Gaucher disease is a rare, autosomal recessive disease caused by mutations in the GBA1 gene, which encodes the enzyme glucocerebrosidase.4,5 This enzyme is required for the normal function of lysosomes – a component of the cell that degrades unwanted materials.1,3,5 It was in the treatment of Gaucher disease that researchers noted that there were higher proportions of patients with PD than would otherwise be expected, highlighting GBA1 as a shared risk factor for both Gaucher disease and PD.4 The increasing understanding of GBA1-driven PD pathology has led to some promising avenues of treatment research, including the idea of using virus vectors to deliver wild-type glucocerebrosidase to neurons, and the use of small molecule chaperone proteins to increase the levels of properly folded glucocerebrosidase within cells.2 

file_download Download in HQ

Related content

image Image Image showing mechanisms for targeting α-synuclein in Parkinson’s disease research
Possible α-synuclein targets for development of therapies for Parkinson’s disease

Overview of three therapeutic strategies targeting alpha-synuclein in the development of disease-modifying treatments for Parkinson’s disease

26.06.2025 Parkinson’s Disease
image Image Image showing potential effects of disease-modifying treatments on Parkinson’s disease progression
Disease modification in Parkinson’s disease

Graphical representation of how various treatment strategies can impact disease progression in Parkinson’s disease, from symptom relief to potential cure

26.06.2025 Parkinson’s Disease
image Image Image showing how COMT inhibitors increase dopamine availability
Catechol-O-methyltransferase (COMT) inhibitors mechanism of action

Illustration of how COMT inhibitors increase dopamine availability in Parkinson’s disease by preventing the breakdown of L-DOPA

26.06.2025 Parkinson’s Disease